Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
FATE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.04 - $8.83
Previous CloseN/A
Volume630.90K
Average Volume (3M)2.23M
Market Cap
$174.26M
Enterprise Value$214.25M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.14
Next Earnings
Mar 03, 2025EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding113,894,330
10 Day Avg. Volume2,654,112
30 Day Avg. Volume2,229,508
Standard Deviation0.25
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.96
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.18
Enterprise Value/Ebitda-1.20
Forecast
1Y Price Target
$7.75Price Target Upside353.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Fate Therapeutics News
PremiumCompany Announcements
Fate Therapeutics Announces Executive Leadership Transition
PremiumCompany Announcements
Fate Therapeutics Announces Leadership Transition for 2025
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsFT819 shows rapid and sustained B-cell depletion, demonstrating promising results in the treatment of auto-immune diseases.
Clinical OutcomesThe first patient treated with FT819 for refractory lupus nephritis achieved complete clinical remission without any CRS or ICANS, indicating a compelling clinical signal.
Financial OutlookThe company ended the quarter with a cash position expected to fund operations through the end of 2026, providing financial stability for ongoing research.
Bears Say
Product DevelopmentFT596 showed low activity in DLBCL, supporting the company's decision to halt further development for the asset.
Program PrioritizationClarity is needed on how the FT522 program will be prioritized amid the company's ongoing platform shift to autoimmune therapies.
Treatment DurabilityThe repopulation of B cells in FATE's study appears faster than in autologous CAR T studies, raising concerns about the durability of the treatment.
---
Ownership Overview
18.28% Insiders
16.23% Mutual Funds
39.53% Other Institutional Investors
15.52% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $1.04 and its highest was $8.83 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is $174.26M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Mar 03, 2025 which is in 11 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.416 by $0.016.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.44.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 113,894,330 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.416. Following the earnings report the stock price went down -8.824%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in FATE
---
Fate Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.75 (353.22% Upside)
$7.75 (353.22% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $63.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.38%
12-Months-Change
Fundamentals
Return on Equity
-49.19%
Trailing 12-Months
Asset Growth
-8.98%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
---
FATE Stock 12 Month Forecast
Average Price Target
$7.75
▲(353.22% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering FATE
1 Year
1 Year Success Rate
4/16 ratings generated profit
1 Year Average Return
-22.34%
assigned a buy rating last month
Copying Peter Lawson's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -22.34% per trade.
---